Neoplasms/Lymphoma/Leukemia
|
|
|
- Isaac Freeman
- 6 years ago
- Views:
Transcription
1 Neoplasms/Lymphoma/Leukemia
2 Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and coding Next scheduled webinar: May Topic: Neurologic Disease CNC does not accept responsibility or liability for any adverse outcome from this training for any reason including undetected inaccuracy, opinion, and analysis that might prove erroneous or amended, or the coder/physician s misunderstanding or misapplication of topics. Application of the information in this training does not imply or guarantee claims payment.
3 Agenda HCC Categories ICD-10-CM Classification Neoplasms Benign (non cancerous) Malignant Metastatic (secondary) Lymphomas Leukemia, Myeloma and Plasma Cell Neoplasms Guidelines & Documentation Tips
4 Neoplasm HCC Categories HCC Description Trumped HCC 8 Metastatic Cancer and Acute Leukemia 9,10,11,12 9 Lung and Other Severe Cancers 10,11,12 10 Lymphoma and Other Cancers 11,12 11 Colorectal, Bladder, and Other Cancers Breast, Prostate, and Other Cancers and Tumors If two or more diagnoses are documented from the same category, the diagnosis that is more severe or complex will trump any others
5 Neoplasm - Classification ICD-10-CM Chapter 2, Neoplasm (C00-D49) classifies neoplasms by anatomic site and by behavior as: Benign (noncancerous) Malignant (cancerous) In situ (in original place) Uncertain behavior Unspecified behavior Coding Note Uncertain behavior is used when the neoplasm behavior cannot be determined pathologically. Unspecified behavior is used when the behavior is not stated. Code blocks within each behavior subsection are arranged anatomically by the site involved
6 Neoplasm - Benign There are few benign neoplasms that risk adjust. These pertain to the meninges, brain, CNS, and endocrine glands D32.0 Benign neoplasm of cerebral meninges D32.1 Benign neoplasm of spinal meninges D32.9 Benign neoplasm of meninges, unspecified D33.0 Benign neoplasm of brain, supratentorial D33.1 Benign neoplasm of brain, infratentorial D33.2 Benign neoplasm of brain, unspecified D33.3 Benign neoplasm of cranial nerves D33.4 Benign neoplasm of spinal cord D33.7 Benign neoplasm of other specified parts of central nervous system D33.9 Benign neoplasm of central nervous system, unspecified D35.2 Benign neoplasm of pituitary gland D35.3 Benign neoplasm of craniopharyngeal duct D35.4 Benign neoplasm of pineal gland
7 Neoplasm - Malignant C00-C14 C15-C26 C30-C39 C40-C41 C43 C45-C49 C50 C51-C58 C60-C63 C64-C68 C69-C72 C73-C75 C7A C7B C76-C80 C81-C96 Malignant neoplasms of lip, oral, cavity and pharynx Malignant neoplasms of digestive organs Malignant neoplasms of respiratory and intrathoracic organs Malignant neoplasms of bone and articular cartilage Malignant melanoma of skin Malignant neoplasms of mesothelial and soft tissue Malignant neoplasm of breast Malignant neoplasm of female genital organs Malignant neoplasm of male genital organs Malignant neoplasm of urinary tract Malignant neoplasm of eye, brain and other parts of CNS Malignant neoplasm of thyroid and other endocrine glands Malignant neuroendocrine tumors Secondary neuroendocrine tumors Malignant neoplasm of ill-defined, other secondary and unspecified sites Malignant neoplasm of lymphoid, hematopoietic and related tissue
8 Neoplasm Seondary C7B C77 C78 C79 Secondary neuroendocrine tumors Secondary and unspecified malignant neoplasm of lymph nodes Secondary malignant neoplasm of respiratory and digestive organs Secondary malignant neoplasm of other and unspecified sites C80 Disseminated malignant neoplasm, unspecified Use only in those cases where the patient has advanced metastatic disease and no known primary or secondary sites are specified. It should not be used in place of assigning codes for the primary site and all known secondary sites. RAF 2.625
9 Neoplasm - Lymphoma Lymphoma is the most common blood cancer. There are two forms of lymphoma: Hodgkin lymphoma (HL) and non-hodgkin lymphoma (NHL). 4 th digit identifies the type C81.-- Hodgkin lymphoma C81.0- Nodular lymphocyte predominant C81.1- Nodular sclerosis C81.2- Mixed cellularity C81.3- Lymphocyte depleted C81.4- Lymphocyte-rich C81.7- Other (Classical Hodgkin Lymphoma, NOS) C81.9- Unspecified C82.-- Follicular lymphoma C82.0- Grade I C82.1- Grade II C82.2- Grade III, unspecified C82.3- Grade IIIa C82.4- Grade IIIb C82.5- Diffuse follicle center C82.6- Cutaneous follicle center C82.8- Other types C82.9- Unspecified C83.-- Non-follicular lymphoma C83.0- Small cell B-cell C83.1- Mantle cell C83.3- Diffuse large B-cell C83.5- Lymphoblastic (diffuse) C83.7- Burkitt C83.8- Other non-follicular C83.9- Non-follicular (diffuse), unspecified
10 Neoplasm - Lymphoma Lymphoma s are further classified by the anatomical site. 5 th digit identifies the anatomical sites Unspecified site Head, face, and neck Intrathoracic Intra-abdominal Axilla and upper limb Inguinal region and lower limb Intrapelvic Spleen Multiple sites Extranodal and solid organ sites
11 Neoplasm Leukemia, Myeloma, Plasma Cell C90 C91 C92 C93 C94 C95 Multiple myeloma and malignant plasma cell neoplasms Lymphoid leukemia Myeloid leukemia Monocytic leukemia Other leukemias of specified cell type Leukemia of unspecified cell type Specific codes for leukemia's and malignant plasma cell neoplasms indicate whether or not remission has been achieved Not having achieved remission In remission In relapse C96 Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue NOT classified with any remission or relapse
12 Neoplasm Coding Guidelines The ICD-10-CM Official Guidelines for Coding and Reporting are rules that supplement the conventions and instructions within the ICD-10-CM classification. Adherence to these guidelines is required under the Health Insurance Portability and Accountability Act (HIPAA). Guideline When a primary malignancy has been previously excised or eradicated from its site, there is no further treatment (of the malignancy) directed to that site, and there is no evidence of any existing primary malignancy, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Don t confuse personal history with in remission. Codes for leukemia, multiple myeloma, and malignant plasma cell neoplasms indicate whether the condition has achieved remission.
13 Neoplasm Coding Guidelines Leukemia, Multiple Myeloma, and Malignant Plasma Cell Neoplasms in remission versus personal history Guideline The categories for leukemia, and category C90, Multiple myeloma and malignant plasma cell neoplasms, have codes indicating whether or not the leukemia has achieved remission. There are also codes Z85.6, Personal history of leukemia, and Z85.79, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues. If the documentation is unclear as to whether the leukemia has achieved remission, the provider should be queried.
14 Neoplasm Documentation Tips
15 Neoplasm Documentation Tips
16 Neoplasm Documentation Tips
17 Neoplasm Documentation Tips Capturing Severity of Illness (SOI) in ICD-10-CM Terms A patient s SOI is conveyed to CMS and quality organizations via ICD-10-CM codes, assigned by a coder reading the medical record.
18 Questions Please submit coding and documentation questions to
155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary
ICD-9 TO ICD-10 Reference ICD-9 150.9 Malignant neoplasm of esophagus unspecified site C15.9 Malignant neoplasm of esophagus, unspecified 151.9 Malignant neoplasm of stomach unspecified site C16.9 Malignant
Chapter 2 Neoplasms C00-D49 November 11, Chapter 2: Neoplasms Category: C00-D49 Official Coding Guidelines: Section 1.C.2, p.
Chapter 2: Neoplasms Category: C00-D49 Official Coding Guidelines: Section 1.C.2, p. 22 1 C00 C75 Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, hematopoietic
Cancer Association of South Africa (CANSA)
Cancer Association of South Africa (CANSA) Fact Sheet on ICD-10 Coding of Neoplasms Introduction The International Statistical Classification of Diseases and Related Health Problems, 10 th Revision (ICD-10)
Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths
RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected
MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
APPENDIX ONE: ICD CODES
APPENDIX ONE: ICD CODES ICD-10-AM ICD-9-CM Malignant neoplasms C00 C97 140 208, 238.6, 273.3 Lip, oral cavity and pharynx C00 C14 140 149 Digestive organs C15 C26 150 157, 159 Oesophagus 4 C15 150 excluding
Introduction to ICD-O-3 coding rules
Introduction to ICD-O-3 coding rules Weena Laddachayaporn, MD National Cancer Institute, Bangkok, Thailand ICD-O-3 The International Classification of Diseases for Oncology Is a coding system for primary
Cancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
CODING PRIMARY SITE. Nadya Dimitrova
CODING PRIMARY SITE Nadya Dimitrova OUTLINE What is coding and why do we need it? ICD-10 and ICD-O ICD-O-3 Topography coding rules ICD-O-3 online WHAT IS CODING AND WHY DO WE NEED IT? Coding: to assign
CLINICAL MEDICATION POLICY
CLINICAL MEDICATION POLICY Policy Name: Opdivo (nivolumab) injection Policy Number: Approved By: Medical Management, Clinical Pharmacy Products: Highmark Health Options Application: All participating hospitals
Chapter 1: Certain Infectious and parasitic diseases (A00-B99)
ICD-10-CM Part 5 Chapter 1: Certain Infectious and parasitic diseases (A00-B99) New sub-chapter: Infections with a predominantly sexual mode of transmission (A50-A64) You will not find: septicemia - rather,
Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)
Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Document Number: IC-0322 Last Review Date: 02/06/2018 Date of Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011,
Comprehensive ICD-10-CM Casefinding Code List for Reportable Tumors for 2018 (Effective Dates: 10/1/2017-9/30/2018)
Comprehensive ICD-10-CM Casefinding Code List for Reportable Tumors for 2018 (Effective Dates: 10/1/2017-9/30/2018) Please refer to your standard setter(s) for specific reporting requirements before using
CPT Codes: The following ICD-10-CM codes support the medical necessity of CPT code 82306:
CPT s: 82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 82652 Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed The following ICD-10-CM codes support the medical necessity of
Vitamin D Assay Testing For services performed on or after
2018 MEDICARE LOCAL COVERAGE DETERMINATION (LCD) - L36692 CPT CODES: 82306, 82652 Vitamin D Assay Testing For services performed on or after 2-3-2017 DLS TEST CODE AND NAME 49907 (1,25 DIHYDROXY) (CPT
Intensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) [For the list of services and procedures that need preauthorization, please refer to www.mcs.com.pr go to Comunicados a Proveedores, and click Cartas Circulares.]
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not recorded =191 (non-melanoma skin cancer) treated as not recorded
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
WLH Tumor Frequencies between cohort enrollment and 31-Dec 2012 DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not
CLINICAL MEDICATION POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICATION POLICY Adcetris (Brentuximab Vedotin) MP-035-MD-WV Provider Notice Date: 07/03/2017 Original Effective Date: 08/03/2017 Annual Approval Date:
CLINICAL MEDICATION POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICATION POLICY Adcetris (brentuximab vedotin) MP-035-MD-DE Provider Notice Date: 08/01/2017 Original Effective Date: 09/01/2017 Annual Approval Date:
S2 File. Clinical Classifications Software (CCS). The CCS is a
S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous
Factors Influencing Health
Factors Influencing Health Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
CLINICAL MEDICAL POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY ADCETRIS (Brentuximab Vedotin) MP-035-MD-DE Provider Notice Date: 11/1/2016 Original Effective Date: 12/1/2016 Medical Management Annual
CLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
ICD-10-CM - Session 2. Cardiovascular Conditions, Neoplasms and Diabetes
ICD-10-CM - Session 2 Cardiovascular Conditions, Neoplasms and Diabetes Agenda General coding guidelines Acute myocardial infarction Hypertension Cerebrovascular accidents and sequelae Neoplasm and history
NOTE: Should you have landed here as a result of a search engine (or other) link, be advised that these files contain material that is copyrighted by
NOTE: Should you have landed here as a result of a search engine (or other) link, be advised that these files contain material that is copyrighted by the American Medical Association. You are forbidden
ANNUAL CANCER REGISTRY REPORT-2005
ANNUAL CANCER REGISTRY REPORT-25 CANCER STATISTICS Distribution of neoplasms Of a total of 3,115 new neoplasms diagnosed or treated at the Hospital from January 25 to December, 25, 1,473 were seen in males
Model Policy. Coverage of Proton Therapy
Model Policy Coverage of Proton Therapy Last Revised - February 2019 INTRODUCTION Proton therapy is a technologically advanced method to deliver curative radiation doses to cancerous tumors. The unique
Contractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC A. LCD ID Number: L35032 Status: A-Approved
LCD for Flow Cytometry (L35032) Contractor Name: Novitas Solutions, Inc. Contractor Number: 12501 Contractor Type: MAC A LCD ID Number: L35032 Status: A-Approved Contractor Information LCD Information
Contractor Information. LCD Information. Local Coverage Determination (LCD): Computerized Axial Tomography of the Chest/Thorax (L34416)
Local Coverage Determination (LCD): Computerized Axial Tomography of the Chest/Thorax (L34416) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor
DATA REQUEST RESPONSE- XRT AND BRACHYTHERAPY
Date: 10 th April 2018 DATA REQUEST RESPONSE- XRT AND BRACHYTHERAPY Request: 1. Utilization Data of Overseas Beam Therapy and Brachytherapy 2. Diagnoses Data of Overseas Claims for Beam Therapy and Brachytherapy
Who What When Where Why. Case Finding 5 W s. NAACCR Webinar Series. Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC
Who What When Where Why Case Finding 5 W s NAACCR 2010-2011 Webinar Series Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC Agenda Case Finding Purpose Reportable lists Benign intracranial
The European Commission s science and knowledge service. Joint Research Centre
The European Commission s science and knowledge service Joint Research Centre Coding Primary Site and Tumour Morphology JRC-ENCR training course Copenhagen, 25 September 2018 Nadya Dimitrova Outline What
SAMPLE. Laboratory Services. An essential coding, billing, and reimbursement resource for laboratory and pathology services ICD-10
Coding and Payment Guide www.optumcoding.com Laboratory Services An essential coding, billing, and reimbursement resource for laboratory and pathology services 2017 ICD-10 A full suite of resources including
BRAF Mutation Analysis
Last Review Date: October 13, 2017 Number: MG.MM.LA.38aC Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
Pembrolizumab (Keytruda )
Last Review Date: March 14, 2017 Number: MG.MM.PH.10f Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
Yescarta (axicabtagene ciloleucel)
Last Review Date: March 30, 2018 Effective Date: April 1, 2018 Number: MG.MM.PH.42 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider
Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
PROPOSED/DRAFT Local Coverage Determination (LCD): CT of the Head (DL34417) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please note: This is a Proposed/Draft
Gamma Glutamyl Transferase
Other Names/Abbreviations GGT 190.32 - Gamma Glutamyl Transferase Gamma glutamyl transferase (GGT) is an intracellular enzyme that appears in blood following leakage from cells. Renal tubules, liver, and
WASHINGTON perspectives
An Analysis and Commentary on Federal Health Care Issues by Larry Goldberg CMS Announces Final Inpatient Psychiatric Facilities PPS Update for FY 2017 The Centers for Medicare and Medicaid Services (CMS)
From A to Z-Codes Matter
From A to Z-Codes Matter Susan Wallace, MEd, RHIA, CCS, CDIP, CCDS, FAHIMA While ALL ICD-10-CM codes are important, the Z-codes in ICD-10-CM are frequently considered step-children, supplemental codes
CLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Oncologic Genetic Testing Panels MP-074-MD-PA Medical Management Provider Notice Date: 11/15/2018 Issue Date: 12/15/2018 Effective
Subject Cancers in Firefighters and Fire Investigators
If a firefighter or a fire investigator is diagnosed with a prescribed on or after January 1, 1960, and meets the employment duration and additional criteria for the prescribed, then the disease is presumed
Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
Session Guidelines. This is a 15 minute webinar session for CNC physicians and staff
Respiratory Disease Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and coding
Nov FromAtoZCodesMatter
Nov 2017 FromAtoZCodesMatter From A to Z-Codes Matter Susan Wallace, MEd, RHIA, CCS, CDIP, CCDS, FAHIMA The implementation of ICD-10 brought tens of thousands of new codes. Ranging from A to Z, they portray
2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
Contractor Information. LCD Information. Local Coverage Determination (LCD): CT of the Abdomen and Pelvis (L34415) Document Information
Local Coverage Determination (LCD): CT of the Abdomen and Pelvis (L34415) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor
REPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2015 and after
REPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2015 and after The following lists are intended to assist you, as the reporter, in identifying the reportable neoplasms for your facility. Any reportable
Update in Lymphoma Imaging
Update in Lymphoma Imaging Victorine V. Muse, MD Lymphoma Update in Lymphoma Imaging Victorine V Muse, MD Heterogeneous group of lymphoid neoplasms divided into two broad histological categories Hodgkin
OP-10: ABDOMEN CT USE OF CONTRAST MATERIAL
Description of Measure OP-10: ABDOMEN CT USE OF CONTRAST MATERIAL This measure calculates the percentage of abdomen studies that are performed with and without contrast out of all abdomen studies performed
Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
Lumbar MRI. Noridian Healthcare Solutions, LLC
Lumbar MRI Noridian Healthcare Solutions, LLC Please Note: This is a Proposed LCD. Proposed LCDs are works in progress and not necessarily a reflection of the current policies or practices. Proposed LCDs
2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018
1 2018 Grade PEGGY ADAMO, RHIT, CTR ADAMOM@MAIL.NIH.GOV OCTOBER 11, 2018 2 Acknowledgements Donna Hansen, CCR Jennifer Ruhl, NCI SEER Introduction 3 Histologic Type vs. Grade Credit: Dr. Kay Washington
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence
Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence In 2014, there were 452 new cancer cases diagnosed and or treated at Truman Medical Center- Hospital Hill and an additional
Contractor Information. LCD Information. Local Coverage Determination (LCD): Flow Cytometry (L34513) Document Information
Local Coverage Determination (LCD): Flow Cytometry (L34513) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name Contract
*
Introduction Cancer is complex, can have many possible causes, and is increasingly common. For the U.S. population, 1 in 2 males and 1 in 3 females is at risk of developing cancer in their lifetime. The
Contractor Information. LCD Information. Local Coverage Determination (LCD): CT of the Abdomen and Pelvis (L34415) Document Information
Local Coverage Determination (LCD): CT of the Abdomen and Pelvis (L34415) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor
Crosswalk File of ICD9 Diagnosis Codes to Risk Group Assignment 1-Apr-15
1 1500 MALIGNANT NEOPLASM OF CERVICAL ESOPHAGUS 1 1501 MALIGNANT NEOPLASM OF THORACIC ESOPHAGUS 1 1502 MALIGNANT NEOPLASM OF ABDOMINAL ESOPHAGUS 1 1503 MALIGNANT NEOPLASM OF UPPER THIRD OF ESOPHAGUS 1
Supplementary Online Content
Supplementary Online Content Acuna SA, Fernandes KA, Daly C, et al. Cancer mortality among recipients of solidorgan transplantation in Ontario, Canada. JAMA Oncol. Published online January 7, 2016. doi:10.1001/jamaoncol.2015.5137
Subject Cancers in Firefighters and Fire Investigators
If a full-time, part-time or volunteer firefighter or a fire investigator suffers from and is impaired by one of the prescribed s described below, and meets the conditions related to duration of employment
California Cancer Registry Production Automation and Quality Control Unit Data Alert - Registrar
Production Automation and Quality Control Unit Data Alert - Registrar 2015-061 REVISED Casefinding List FY2016 Please see additions and revisions noted below in red text. ICD-10-CM Codes have been adopted
Radiation Oncology Study Guide
Radiation Oncology Study Guide For the Initial CertificationQualifying (Computer-Based) Examination General and Radiation Oncology This examination is designed to assess your understanding of the entire
Colony Stimulating Factors: Neupogen (filgrastim), Neulasta (pegfilgrastim), Leukine (sargramostim), Granix (tbo-filgrastim)
Neupogen (filgrastim), Neulasta (sargramostim), Granix (tbo-filgrastim) Date of Origin: 10/17/2008 Dates Reviewed: 6/17/2009, 12/22/2009, 06/15/2010/ 7/20/2010, 09/2010, 12/2010, 03/2011, 06/2011, 09/2011,
Prothrombin Time (PT)
Other Names/Abbreviations PT 190.17 - Prothrombin Time (PT) Basic plasma coagulation function is readily assessed with a few simple laboratory tests: the Partial Thromboplastin Time (PTT), Prothrombin
Annual Report. Cape Cod Hospital and Falmouth Hospital Regional Cancer Network Expert physicians. Quality hospitals. Superior care.
Annual Report Cape Cod Hospital and Falmouth Hospital Regional Cancer Network 2013 Expert physicians. Quality hospitals. Superior care. Cape Cod Hospital s Davenport- Mugar Hematology/Oncology Center and
Substance Use Disorders
Substance Use Disorders Substance Use Disorder This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that
Cheryl Ericson, MS, RN, CCDS, CDIP, AHIMA Approved ICD 10 CM/PCS Trainer Clinical Documentation Program Manager for ezdi.
A Venture of Cheryl Ericson, MS, RN, CCDS, CDIP, AHIMA Approved ICD 10 CM/PCS Trainer Clinical Documentation Program Manager for ezdi HIPAA Code Sets HIPAA legislation required use of the International
Velcade (bortezomib) Document Number: IC-0137
Velcade (bortezomib) Document Number: IC-0137 Last Review Date: 11/21/2017 Date of Origin: 11/28/2011 Dates Reviewed: 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014,
CLINICAL MEDICATION POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICATION POLICY Granulocyte Colony Stimulating Factors (G-CSFs) MP-016-MD-DE Medical Management; Clinical Pharmacy Provider Notice Date:
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
Local Coverage Determination (LCD): Flow Cytometry (L34215) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name Contract
Fusilev (levoleucovorin) Document Number: IC-0183
Fusilev (levoleucovorin) Document Number: IC-0183 Last Review Date: 2/1/2018 Date of Origin: 01/02/2014 Dates Reviewed: 08/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016,
Khapzory (levoleucovorin) (Intravenous)
Khapzory (levoleucovorin) (Intravenous) Last Review Date: 12/04/2018 Date of Origin: 12/04/2018 Dates Reviewed: 12/2018 Document Number: IC-0408 I. Length of Authorization Coverage will be provided for
CODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
Retroperitoneal lymphoma mixed cell type icd 10
Retroperitoneal lymphoma mixed cell type icd 10 The Borg System is 100 % Retroperitoneal lymphoma mixed cell type icd 10 Lymphoma, non hodgkins, stage 1; Lymphoma, non hodgkins, stage 2; Lymphoma, non
CLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Opdivo (nivolumab) MP-004-MC-PA Medical Management; Clinical Pharmacy Provider Notice Date: 09/01/2018; 06/15/2018; 04/01/2017
Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies
Web appendix 2: SEARCH STRATEGIES Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies MEDLINE 1. exp epidemiologic studies/
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry
Leukemia And Lymphoma In The Nervous System
Leukemia And Lymphoma In The Nervous System If you are searching for the book Leukemia and Lymphoma in the Nervous System in pdf format, then you've come to the right site. We presented complete variant
CLINICAL MEDICATION POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICATION POLICY Keytruda (pembrolizumab) MP-014-MD-DE Medical Management; Clinical Pharmacy Provider Notice Date: 01/15/2018; 08/01/2017; 06/01/2016
Classification of Neoplasms
Classification of Neoplasms ICD-10 Chapter 2, Neoplasms Codes C00-D48 Notes at beginning of Chapter 2 Classified by behaviour and site Correct use of Alphabetic index required Main terms Modifiers Table
SKCC Protocol Review Committee New Study Application
Instructions: Submit the following documents to prc@jefferson.edu - Completed New Study Application (aka MCSF) - Protocol - Protocol Facilitation Committee Approval (if applicable) - MDG Priority Score
Pelvic lymph node dissection icd 10 code
Pelvic lymph node dissection icd 10 code. 200/96 SUKHUMVIT 71 RD. BANGKOK 10110 THAILAND TLX: 84236 AZTEC TH FAX: 381-2800 TEL: 391-0765, 381-1688-9, 381-1693 Pelvic lymph node dissection icd 10 code Approximate
2017 ICD-10-CM Casefinding List (Abbreviated listing from SEER website) COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors
2017 ICD-10-CM Casefinding List (Abbreviated listing from SEER website) COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors ICD-10 Code Explanation of Code Malignant neoplasms (excluding
Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014
Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014 Q: If polycythemia ruba vera (PRV) or essential thrombocythemia (ET) is diagnosed by peripheral smear,
Serum Iron Studies
190.18 - Serum Iron Studies Serum iron studies are useful in the evaluation of disorders of iron metabolism, particularly iron deficiency and iron excess. Iron studies are best performed when the patient
HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO
HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO HODGKIN LYMPHOMA CLASSIFICATION Lukes & Butler Rye WHO-2016 Linphocytic and/or histiocytic Nodular & diffuse Nodular Sclerosis Lymphocyte
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
We re on the Web! Visit us at www2.kumc.edu/kcr
VOLUME 18 ISSUE 2 April 2014 We re on the Web! Visit us at www2.kumc.edu/kcr April 7-11 is National Cancer Registrars Week! This week was established as an annual celebration to acknowledge the central
Cancer in Central and South America BOLIVIA
Cancer in Central and South America BOLIVIA This country profile for the Cancer in Central and South America project provides, for each participating cancer registry tables and graphics showing numbers
Tumor Comparison. NAACCR Death Clearance Manual Update. Bobbi Jo Matt, BS RHIT CTR NAACCR 2013 Conference, Austin, TX June 12, 2013
Tumor Comparison NAACCR Death Clearance Manual Update Bobbi Jo Matt, BS RHIT CTR NAACCR 2013 Conference, Austin, TX June 12, 2013 Tumor Comparison The process of comparing the registry s tumors to the
CLIC Sargent Eligibility Criteria
1 Eligibility Criteria DOCUMENT GOVERNANCE: Eligibility criteria Produced by J. Hawkins & Grants Team Sponsored by Dara de Burca Version Approval by Executive Team 10 th June 2014 Board of Trustees 3 rd
Hazelinks - Cancer incidence analysis (First data extraction)
Hazelinks - Cancer incidence analysis (First data extraction) Authors Prof Malcolm Sim Ms Christina Dimitriadis Dr Caroline Gao Mr Anthony Del Monaco 1 1 Contents Abbreviations... 3 Executive Summary...
LCD for Interferon (L29202)
LCD for Interferon (L29202) Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B Contractor Information LCD ID Number L29202 LCD Information LCD Title
LCD L Flow CytometryPrint
LCD L32562 - Flow CytometryPrint Contractor Information Contractor Name: Novitas Solutions, Inc. Contractor Number(s): 12501, 12101, 12102, 12201, 12202, 12301, 12302, 12401, 12402, 12901, 12502 Contractor
Peripheral Nerve Blocks
Last Review Date: April 21, 2017 Number: MG.MM.ME.64v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
Soft tissue metastasis icd 10
Soft tissue metastasis icd 10 Search GO Soft tissue metastasis icd 10 Free, official coding info for 2018 ICD-10-CM C79.51 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and. information